Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received One To Three Lines of Treatment By Ogkologos - June 16, 2026 125 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-9 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Finding New Uses for Targeted Therapies for Cancer: Updates from the... November 9, 2023 Dame Deborah James: why do deeply personal stories resonate with us... May 24, 2022 Mammograms Can Detect COVID-19 Vaccination Swelling, Causing Cancer Scares March 4, 2021 FLT3 Internal Tandem Duplication Measurable Residual Disease in Complete Remission Identifies... November 7, 2022 Load more HOT NEWS Wishes for a New Year! FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and... Mirvetuximab Soravtansine-gynx Shows a Significant Benefit Over Chemotherapy in Women with... Immunotherapy is Beneficial in Gastric and Oesophageal Cancers, Studies Show [ESMO2020...
